Executive Summary
Radial secondary access beats contralateral femoral for the "small" hole in TAVI, cutting secondary-site vascular complications from 3.3% to 0.7% in the SAFER-TAVI trial presented at New York Valves 2026, though the composite primary+secondary bleeding endpoint missed significance and radiation dose rose — a reminder that the second stick still causes a fifth of TAVI vascular events. Institutional volume separately mattered more than device choice in a 91,494-patient Vizient analysis linking higher TAVR volume to lower length of stay and, in 2024, lower observed mortality after CMI adjustment. Meanwhile, single-center octogenarian mitral data (N=221, retrospective) showed 3% operative mortality for surgical repair versus 11% for replacement, undercutting the assumption that transcatheter is the only tenable option at 80+. Together the day tightens the case for high-volume centers and radial secondary access, and loosens the reflex to send every octogenarian to TEER.
- Portico intra-annular self-expanding TAV outperformed SAPIEN 3 on PPM (3.3% vs 26.3%) in small annuli at 30 days and showed lower 5-year SVD (2.2% vs 13.9%) in PORTICO IDE core-lab analysis.
- Myval real-world single-center registry (N=214) reported 97.7% procedural success and 3.4% SVD at up to 3 years, extending LANDMARK trial signals into routine practice.
- Medtronic issued a heart valve delivery system recall for safety risk, per Cardiovascular Business.
- Edwards investors moved for first approval of a $39M securities-litigation settlement ahead of July 23 earnings.
What to watch: Edwards' Q2 earnings on July 23 will test whether TAVR ASP and TEER growth support the 12% six-month rally in EW shares.
Aortic Valve (TAVR/TAVI)
Volume and access technique — not the next-generation valve — drove today's most actionable TAVR data. The Vizient analysis of 91,494 non-Impella TAVRs across 118 US hospitals from 2022-2024 found higher institutional volume independently associated with shorter LOS every year and, in 2024, lower observed mortality after CMI adjustment (ANCOVA p<0.0001). The signal is consistent but the design is claims-based, non-randomized, and cannot adjust for unmeasured operator-level factors. Still, it argues against continued proliferation of low-volume TAVR programs — a policy question CMS revisits periodically.
On the device side, the PORTICO IDE core-lab analysis is more provocative than its EuroIntervention framing suggests: Portico matched supra-annular Evolut on EOA in small annuli and crushed SAPIEN 3 on severe PPM (3.3% vs 26.3%), with 5-year SVD of 2.2% vs 13.9% versus SAPIEN 3 in small annuli (industry-sponsored, high/extreme-risk cohort, N=675). A separate single-center Myval registry (N=214, retrospective, no comparator) reported 97.7% success and stable gradients at 3 years, consistent with LANDMARK non-inferiority. SAFER-TAVI — 542 patients, three Melbourne centers, open-label — showed radial secondary access cut secondary-site vascular complications 5-fold at the cost of more radiation and more crossovers to alternate access. Surgical counterpoint: none of this changes the ACC/AHA 2020 Class I recommendation for SAVR under 65 or the ESC 2025 SAVR-preferred threshold under 70 in low-risk anatomy; PPM and SVD in small annuli remain reasons SAVR with annular enlargement is still on the table for younger women.
Mitral Valve (MitraClip, PASCAL, TMVR)
Surgical repair remains the answer for degenerative MR at 80+, and today's data sharpens that claim. A JTCVS single-center series of 221 octogenarians (retrospective, high-volume center, 2015-2024) reported 3% operative mortality after mitral repair versus 11% after replacement, with 1.2% mortality in the DMR subgroup (N=168) regardless of procedure and a mid-term survival advantage for repair out to 4 years. STS-PROM was 5%. This directly contradicts the framing — common in TEER marketing — that octogenarians are categorically too frail for surgery. The JACC Imaging editorial on residual MR–mean gradient trade-off reinforces a related tension in M-TEER: aggressive leaflet grasping to eliminate residual MR raises transmitral gradient, and neither endpoint alone captures durable benefit.
Guideline anchor: ACC/AHA 2020 rates PMR repair Class I when durable results are expected; ESC 2025 upgraded early repair in asymptomatic PMR to Class I when at least 3 of AF, PH, LA dilation, or moderate TR are present. Neither guideline exempts octogenarians. Pikeville Medical Center's first solo MitraClip is a program-maturation note, not a clinical finding.
Tricuspid Valve (TriClip, TTVR)
Program dispersion continues faster than the outcomes literature. St. Francis Medical Center performed the first TriClip in Northeast Louisiana, part of a broad first-case rollout wave. That expansion sits on ESC 2025 Class IIa (LOE A) for transcatheter TV treatment in high-risk symptomatic severe TR without severe RV dysfunction — a designation earned by TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II. ACC/AHA 2020 predates all three trials. A Methodist DeBakey review of TEER in adult congenital heart disease catalogs the anatomic obstacles — anomalous venous return, distorted transseptal geometry, systemic tricuspid morphology in ccTGA — that make published TR TEER outcomes non-generalizable to ACHD. Surgical counterpoint remains uncomfortable: ESC 2025 upgraded surgery for symptomatic severe primary TR to Class I, but real-world isolated TV surgery mortality historically 8-20% keeps most operators on the transcatheter side of the coin flip. The unresolved question is whether community first-case programs can replicate TRILUMINATE Pivotal's safety profile without the imaging depth and case selection of trial centers.
Surgical vs. Transcatheter Comparisons
No head-to-head randomized data today, but three signals converge. The octogenarian mitral surgery series shows 1.2% operative mortality in DMR at a high-volume center — a benchmark TEER should be measured against in this age group, not simply assumed to beat. PORTICO IDE's 5-year SVD signal (2.2% Portico vs 13.9% SAPIEN 3 in small annuli) is exactly the durability granularity SAVR-versus-TAVR debates need but rarely get; note the high/extreme-risk enrollment limits extrapolation to the low-risk populations now driving TAVR indication creep. And the Vizient volume-outcome analysis reframes the SAVR-vs-TAVR question institutionally: a low-volume TAVR program may not be safer than a high-volume surgical program for the same patient.
Device & Technology
Two case reports illustrate the increasingly baroque bailouts required when transcatheter therapy fails or complicates: single-session PVL closure plus valve-in-valve TAVR 8 years post-Evolut for mixed transvalvular and paravalvular regurgitation, and bailout M-TEER for SAM-induced severe MR during TAVI without LVOT obstruction. Both are N=1, both worked, both should be read as reminders that lifetime-management planning at the index TAVR — the ESC 2025 emphasis on future valve-in-valve feasibility, coronary access, and PPM — is not academic.
Regulatory & Policy
[NOTABLE] Medtronic recalled a heart valve delivery system for safety risk, per Cardiovascular Business. Details on scope and device family remain limited pending FDA classification, but the timing — mid-Q2, ahead of the August 18 earnings — will be scrutinized. Medtronic's structural heart franchise is already the weakest performer among our tracked names on a 6-month basis.
Industry & Market
Edwards investors sought first approval of a $39M settlement, per Law360 — a housekeeping item ahead of July 23 earnings, but a reminder that the 2023 TAVR growth guidance reset left litigation residue. Edwards is separately highlighting its structural heart portfolio to investors — PASCAL, EVOQUE, and SAPIEN 3 Ultra RESILIA together anchor the growth narrative.
Financial Analysis
The tape today reflects clinical fundamentals more than usual. Edwards up 12% over six months maps cleanly to EARLY TAVR tailwinds, EVOQUE STS/ACC TVT Registry data, and the ESC 2025 tricuspid Class IIa upgrade. Boston Scientific down 55% on the six-month look — the most severe move in the group — sits against Watchman and PFA competition dynamics that our sources don't detail today. Medtronic down 15% and now facing a valve delivery system recall is the setup story for August 18 earnings. Abbott down 24% despite MitraClip and TriClip franchise strength suggests broader diagnostics-related pressure rather than valve-specific concerns. Anteris up 111% is a small-cap early-stage story on DurAVR data; without US pivotal readouts, it's optionality, not fundamentals.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $95.18 (+0.86%), near six-month high of $95.57; 6-month change +12.20%
- Market cap $54.8B; trailing P/E 51.45, forward P/E 28.26; beta 0.85; 52-week range $72.30–$95.56
- Analyst consensus buy, target $97.31 (range $84–$110, 26 analysts)
- Next earnings July 23 (EPS est $0.74, Rev est $1.70B)
- Structural heart franchise remains the growth story: SAPIEN 3 Ultra RESILIA, PASCAL, and EVOQUE all contributing. $39M investor settlement now near first approval.
Medtronic (MDT)
- Close: $83.06 (-0.16%); 6-month change -15.31%
- Market cap $106.3B; trailing P/E 22.27, forward P/E 12.97; beta 0.58; 52-week range $73.31–$106.33
- Analyst consensus buy, target $97.77 (range $78–$121, 26 analysts)
- Next earnings August 18 (EPS est $1.39, Rev est $9.55B)
- Heart valve delivery system recall today adds pressure on Evolut narrative; forward P/E under 13 reflects sustained skepticism.
Abbott (ABT)
- Close: $95.63 (+0.24%); 6-month change -23.87%
- Market cap $166.6B; trailing P/E 26.79, forward P/E 15.79; beta 0.61; 52-week range $81.97–$137.49
- Analyst consensus buy, target $116.72 (range $92–$135, 25 analysts)
- Next earnings July 16 (EPS est $1.28, Rev est $12.52B)
- MitraClip and TriClip franchises intact; six-month decline appears diagnostics-driven rather than structural heart.
Boston Scientific (BSX)
- Close: $44.60 (-1.20%); 6-month change -54.79%, worst in the group
- Market cap $66.3B; trailing P/E 18.66, forward P/E 12.01; beta 0.58; 52-week range $42.25–$109.50
- Analyst consensus strong buy, target $75.00 (range $55–$106, 29 analysts) — implied upside 68%
- Next earnings July 29 (EPS est $0.83, Rev est $5.37B)
- Analyst-vs-tape gap is the widest in the sector. Reset expectations meet earnings.
Anteris Technologies (AVR.AX)
- Close: A$15.30 (+3.38%); 6-month change +111.33%
- Market cap $1.5B; forward P/E -7.02 (unprofitable); beta 0.73; 52-week range A$4.68–$15.47
- Single analyst target A$13.00; DurAVR biomimetic single-piece leaflet valve remains preclinical/early clinical
- Speculative small-cap; no US pivotal data.
The sector split — Edwards higher on structural heart execution, Boston Scientific and Medtronic sharply lower on competitive and quality issues — argues against treating "valve stocks" as a single trade. Underlying evidence increasingly rewards clean structural heart franchises with tight execution over conglomerate exposure.
Clinical Trial Updates
SAFER-TAVI was the marquee late-breaker at New York Valves 2026, with results published in tandem via TCTMD. The Vizient volume-outcome analysis and PORTICO IDE 5-year data are the substantive additions to the peer-reviewed literature this week. No new randomized data on early intervention in asymptomatic AS, TEER for atrial functional MR, or TTVR beyond the STS/ACC TVT Registry signal from last week.
Next up: Abbott earnings July 16, then Edwards July 23. Both will indicate whether ESC 2025 tricuspid Class IIa is translating into procedural volume yet, or whether the guideline upgrade remains ahead of the reimbursement and referral pipeline.